If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
149
results.
Updated on
15/11/2026 [07:08:00]
Absstract of: US20260359985A1
Methods and systems for detecting glycosylated haemoglobin (HbA1c) levels from at least one fundus image are disclosed. At least one fundus image associated with an individual is processed using a first set of one or more convolutional neural networks to determine a glycosylated haemoglobin (HbA1c) level for the at least one fundus image. Methods and systems of determining a risk level of progression of diabetic retinopathy of an individual are also disclosed. At least one fundus image associated with the individual is processed using a second set of one or more convolutional neural networks to determine a retinopathy grade for the at least one fundus image. A risk level of progression of diabetic retinopathy of the individual is determined based on at least the HbA1c level and the retinopathy grade.
Absstract of: US20260355256A1
Disclosed herein are compositions and methods to differentiate pancreatic cells into functional insulin-producing CD133/Ki-67-positive activated islet proliferating cells (AIPCs) derived from isolated pancreatic islets and expand derived-AIPCs in in vitro cultures using a culture medium comprising an active agent. Also disclosed herein is the use of the AIPCs for implantation into a mammal for in vivo therapy, specifically for pancreatic disorders, including diabetes type I.
Absstract of: US20260357194A1
A cell culture medium, kits, and methods for restoring physiological relevance by eliminating the artificial “diabetic” state typical of conventional media is described. The medium comprises a basal medium, insulin, a carrier protein (such as recombinant human serum albumin, cyclodextrin, or a synthetic polymer), and C-peptide. The concentration of C-peptide, ranging from 0.1 mg/L to 1.5 mg/L, is maintained in an approximately equimolar ratio with insulin, adjusted based on the medium's glucose concentration. This supplementation modulates coordinated signaling through the Insulin Receptor (IR), G-protein coupled receptor 146 (GPR146), and the Elastin Receptor Complex, leading to reduced cellular stress and improved metabolism. The invention enhances the production of therapeutic molecules (e.g., antibodies with reduced acidic charge variants) and improves the function of therapeutic cells (e.g., T-cells with a statistically significant reduction in exhaustion markers PD-1 and TIM-3). The carrier, present at a minimum concentration of 10 mg/L, ensures the bioavailability and stability of C-peptide in the medium.
Absstract of: US20260354721A1
A continuous glucose monitoring system may utilize externally sourced information regarding the physiological state and ambient environment of its user for externally calibrating sensor glucose measurements. Externally sourced factory calibration information may be utilized, where the information is generated by comparing metrics obtained from the data used to generate the sensor's glucose sensing algorithm to similar data obtained from each batch of sensors to be used with the algorithm in the future. The output sensor glucose value of a glucose sensor may also be estimated by analytically optimizing input sensor signals to accurately correct for changes in sensitivity, run-in time, glucose current dips, and other variable sensor wear effects. Correction actors, fusion algorithms, EIS, and advanced ASICs may be used to implement the foregoing, thereby achieving the goal of improved accuracy and reliability without the need for blood-glucose calibration, and providing a calibration-free, or near calibration-free, sensor.
Absstract of: US20260354770A1
A system and method provides a glucose report for determining glycemic risk based on an ambulatory glucose profile of glucose data over a time period, a glucose control assessment based on median and variability of glucose, and indicators of high glucose variability. Time of day periods are shown at which glucose levels can be seen. A median glucose goal and a low glucose line provide coupled with glucose variability provide a view into effects that raising or lowering the median goal would have. Likelihood of low glucose, median glucose compared to goal, and variability of glucose below median provide probabilities based on glucose data. Patterns can be seen and provide guidance for treatment.
Absstract of: US20260354745A1
A method for estimating a skin condition includes the steps of: acquiring mind-body data relating to the body and/or mind of a subject of skin condition estimation; estimating the subject's skin condition using a skin model that describes a correlation between the mind-body data and the skin condition, the mind-body data including at least one of liver function related variables, muscle-bone related variables, heart rate and blood pressure related variables, blood oxidation related variables, blood count related variables, lipid metabolism related variables, autonomic function related variables, personal attribute related variables, renal function related variables, body composition related variables, glucose tolerance related variables, electrolyte related variables, cognitive function related variables, immunometabolism related variables, and depression-fatigue-drowsiness related variables.
Absstract of: US20260356979A1
The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (PCSK9). The formulations may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.
Absstract of: DE102025001540A1
Die Erfindung kombiniert ein innovatives, elektromagnetisch betriebenes Injektionssystem mit der medizinischen Anwendung eines bekannten Wirkstoffs zur Behandlung von Adipositas. Das System ermöglicht die nadellose, präzise und nachhaltige Applikation von GLP-1-Analoga wie Semaglutid. Die Technologie reduziert Müll, verbessert die Therapietreue und bietet eine moderne Lösung für chronische Erkrankungen wie Adipositas und Typ-2-Diabetes.
Absstract of: US20260356907A1
The present disclosure provides methods for lowering the blood glucose of a target subject, including for treating diabetes, by administering recombinantly manufactured ultra-long acting insulin-Fc fusion proteins.
Absstract of: EP4838538A2
0001 Exemplary embodiments may provide a user interface and logic for assisting a user in calculating a proper medicament bolus dosage. The user interface may be simple and easy to understand. The user interface may clearly specify needed inputs, such as a carbohydrates amount for a meal that is about to be ingested and the current glucose level reading for the user. Entered inputs may be displayed on the user interface. The user interface may depict key calculated values resulting from calculations that involve the inputs, including the total bolus dosage calculation. The user interface also may depict the values that contribute to the total bolus dosage calculation. Some of the input values, such as carbohydrates amount, may be prepopulated by the management device or medicament delivery device. The user interface may permit overriding of prepopulated input values.
Absstract of: EP4837505A2
0001 The present invention relates to a body attachment unit for continuous glucose monitoring. The present invention provides a body attachment unit for continuous glucose monitoring, wherein: the body attachment unit is manufactured in the state in which the body attachment unit is assembled in an applicator, and thus separate additional work is minimized and the body attachment unit can be attached to the body by simply operating the applicator; in particular, a wireless communication chip is disposed in the body attachment unit so as to communicate with an external terminal, and thus simple and convenient use can be achieved without any additional work for connection of a separate transmitter and maintenance and management can also be easily performed; and the monitoring operation is started by a user's manipulation after the body attachment unit is attached to the body, and thus the user can adjust the operation start time to an appropriate point as necessary and the operation can be started in a stabilized state so as to enable more accurate glucose monitoring.
Absstract of: US20260345037A1
An insulin device configured to control insulin dosage adapts a basal rate profile, using a sensor configured to produce a blood glucose level measurement data, and detect changes of the blood glucose level measurement data over time. A processor is configured to receive the blood glucose level measurement data and a basal rate profile. A basal rate set point corresponds to an insulin delivery reference for a nominal blood glucose. The insulin device includes an insulin dispensing valve controlled by the processor to administer insulin in accordance with the received basal rate profile. The processor is configured to update the basal rate set point over a time period based on both an assessment of at least one of a risk of hyperglycemia and a risk of hypoglycemia from historical blood glucose data, and patterns of actions taken by the insulin device to mitigate glycemic risk during the time period.
Absstract of: US20260345778A1
0000 Provided are improved methods for making immune effector cells, as well as improved immune effector cells generated using the methods. The improved T cells have improved respiratory capacity and mitochondrial mass. Adoptive T cell immunotherapies using such cells demonstrate improved survival, expansion, and persistence in vivo.
Absstract of: WO2026230789A1
A device for predicting blood glucose on the basis of multiple logistic regression, according to an embodiment of the present invention, comprises: an input unit via which food information regarding a target food to be consumed by a user is input; a memory in which user information, dietary habit information, and insulin information are stored; and a processor which determines one or more first and second parameters by modeling, using first and second logistic functions respectively, a relationship between food information (a first input variable) and an increase in blood glucose and a relationship between insulin information (a second input variable) and a decrease in blood glucose, and simulates a postprandial blood glucose curve by applying the first and second parameters to derivatives of the first and second logistic functions, respectively.
Absstract of: US20260345090A1
Conditions of pathophysiologic dysglycemia, associated with type 1 diabetes, can be detected early, including in children. Glycemia data is collected by continuous glucose monitoring devices connected to a cloud server. The server learns person-specific patterns of glycemia and trains a model accordingly, which may serve as a baseline for comparison or as the basis for prediction of future patterns. Such models are conditioned by risk factors and various concurrent activities such as exercise and consumption of sugars. Person-specific models trained at different time periods give different simulated patterns of glycemia. Deviations between the simulated patterns, or between the predicted and actual patterns, can indicate progression of pathophysiologic dysglycemia and type 1 diabetes. These models and comparisons can be further interpreted by the software to result in a reported recommendation for additional diagnostic testing or a reported conclusion of diagnosis and recommendation of preventative intervention.
Absstract of: US20260345036A1
A system and method for glucose estimation. In some embodiments, a system includes: a first glucose-sensing electrode; and a second glucose-sensing electrode, the first glucose-sensing electrode and the second glucose-sensing electrode being configured to be implanted, separated by less than 5 mm, in a subject.
Absstract of: US20260345035A1
0000 A blood glucose monitoring module with composite-wavelength light source and a wearable device comprising the same. The blood glucose monitoring module comprises a light-emitting component and a light-sensing component. The light-emitting component includes a plurality of light source elements configured to emit a plurality of light beams toward a subject. The light beams have wavelengths ranging from 700 nm to 1700 nm. The light beams include at least one first wavelength band and at least one second wavelength band. The at least one first wavelength band is for calibrating depth-dependent optical properties of skin tissue. The at least one second wavelength band is for detecting absorption intensity associated with blood glucose. The light-sensing component is disposed adjacent to the light-emitting component and is configured to receive diffusely reflected optical signals reflected from the subject after being illuminated by the light beams, thereby acquiring optical characteristics indicative of blood glucose concentration.
Absstract of: US20260345089A1
Embodiments relate to an adaptive glycemia monitoring and forecasting system that includes an event monitor configured to receive blood glucose levels of an individual or information about an activity performed by the individual, and generate an event output. The system includes a control module configured to pull observation data, predictor variables, and population estimated vector of covariate weightings coefficients from a database, and generate updated estimated vector of covariate weightings coefficients for the individual user based on the event output. The updated estimated vector of covariate weightings coefficients are determined by a cross-entropy loss objective function. The updated estimated vector of covariate weightings coefficients are used to predict at least one or more of a predicted hypoglycemia state, a predicted normal glycemia state, or a predicted hyperglycemia state for the individual user.
Absstract of: US20260345904A1
Disclosed are a system, methods and computer-readable medium products that provide bolus dosage calculations by a control algorithm-based drug delivery system that provides automatic delivery of a drug, such as insulin or the like, based on sensor input. Blood glucose measurement values may be received at regular time intervals from a sensor. Using the blood glucose measurements, the control algorithm may perform various calculations and determinations to provide an appropriate bolus dosage. The appropriate bolus dosage may be used to respond to a trend in a trajectory of blood glucose measurements. In addition, a bolus dosage may also be determined by the disclosed device, system, method and/or computer-readable medium product in response to an indication that a user consumed a meal.
Absstract of: US20260345053A1
0000 Cardiovascular diseases and diabetes pose significant threats to human health. Continuous monitoring of physiological parameters, including blood pressure, baroreflex sensitivity (BRS), and cardiac contractility, is critical for effective disease management. The present invention provides a multitask pipeline neural network system that utilizes a single-lead electrocardiogram (ECG), particularly a lead I ECG signal obtained from a wearable device, as an input to estimate multiple physiological parameters on a beat-to-beat basis. The system is applicable to cuffless continuous blood pressure estimation, pain assessment, bedside monitoring, and diabetes screening. Furthermore, the invention can be extended to evaluate aging indices, brain function, cardiac function, autonomic nervous system (ANS) activity, and overall cardiovascular system performance. The invention provides a scalable and market-competitive solution for home healthcare and medical industries, offering high industrial applicability and commercial value.
Absstract of: US20250213785A1
Disclosed herein are improved infusion sets that incorporate halogenated siloxane materials within the composition of an infusion set septum. Such configurations maintain the mechanical robustness of using elastomeric materials for a fluidic septum while providing barrier properties that prevent phenolic preservative from being absorbed out of the infusion set. Infusion sets as disclosed herein are particularly suitable for maintaining insulin's anti-microbial effectiveness over extended wear (e.g., 7 days) to maintain performance of the infusion set during extended wear and reduce the risk of insulin aggregate propagation.
Absstract of: WO2025141541A1
Systems and methods are provided for enabling and disabling insulin pumps in a multi- pump insulin pump system. For example, multiple pumps (e.g., patch pumps) may be rotated to deliver insulin to a user. In one example, one patch pump may be worn while another patch pump is charging. Once the battery of the patch pump worn by the user is depleted, a mobile device may cause the enabled pump in operation and worn by the user to send the latest pump settings and configuration data to the mobile device which will share the information with the disabled pump. The disabled pump will then update the pump settings based on this information and the mobile device may active the pump such that is now enabled for insulin delivery. The mobile device may also facilitate pairing between the patch pumps and a CGM device as they enabled for use and disabled.
Absstract of: EP4834208A2
0001 The present invention relates to a continuous blood glucose measurement device which is produced with an assembled body attachment unit inside an applicator so as to minimize a user s additional work of attaching the body attachment unit to the body, thereby enabling the body attachment unit to be attached to the body by simply activating the applicator, and, particularly, the present invention provides a continuous blood glucose measurement device which is provided with a wireless communication chip in a body attachment unit so as to enable communication with an external terminal, thereby enabling simple and convenient use, without additional work of connecting a separate transmitter, and easier maintenance and is activated by the user after the body attachment unit is attached to the body so as to enable the operation start time to be adjusted to an appropriate time according to user s needs, and to enable the operation to start in a stabilized state so that blood glucose can be measured more accurately.
Absstract of: LU505951B1
A method performed by a computer system for monitoring diabetes and comprising: a model explainability phase, comprising steps of: - collecting specific foot data from at least one sensor disposed at least within a shoe insole of a user, - collecting a plurality of trained machine learning models configured for decision-making in diabetes diagnosis based on a plurality of collected data, - based on the plurality of trained machine learning models, generating a plurality of specific machine learning models, said specific machine learning models being specified for decision-making in diabetes diagnosis based on the specific foot data, and a model reliability assessment phase, comprising steps of: - evaluating a reliability of each of the specific machine learning model based on neutrosophic sets and intuitionistic fuzzy sets, - based on the result of the evaluation step, selecting the optimized machine learning model for monitoring diabetes based on the specific foot data.
Nº publicación: EP4832934A1 04/11/2026
Applicant:
TANDEM DIABETES CARE INC [US]
Tandem Diabetes Care, Inc.
Absstract of: WO2025145056A1
Disclosed herein are apparatuses and methods that account for exercise in closed loop insulin delivery systems. The apparatuses and methods disclosed herein address exercise-induced glucose level increases by reducing the target IOB within the closed loop. By reducing the target IOB, the algorithm responds less aggressively to pre-exercise food, and does not build up the IOB that could potentially contribute to undesirably low glucose levels once the exercise also begins lowering glucose levels. Following exercise, because the user's body will not immediately transition to a pre-exercise state, the algorithm will gradually transition back to the initial target IOB.
BOPI
Electronic site
